Wannan shafin yanar gizon yana amfani da kukis domin mu iya ba ku damar kwarewa mafi kyau. Ana adana bayanin kuki a cikin burauzarka kuma yana aiki da ayyuka kamar gane da ku idan kun dawo zuwa shafin yanar gizon mu da kuma taimaka wa tawagar mu fahimci wane ɓangaren shafin yanar gizon da kuka samu mafi ban sha'awa da amfani.
Kudu (2013)
Kima na preclinical na masu hana PLK 1 don maganin recessive dystrophic epidermolysis bullosa hade da squamous cell carcinoma
Game da kudaden mu
| Jagoran Bincike | Dokta Andrew South, Mataimakin Farfesa, Sashen Nazarin cututtukan fata da Cutaneous Biology Jami'ar Thomas Jefferson, Philadelphia, Amurka |
| Institution | Cibiyar Magungunan Kwayoyin Halitta, Cibiyar Nazarin Clinical, Jami'ar Dundee, Asibitin Ninewells da Makarantar Kiwon Lafiya, Dundee, DD1 9SY, UK |
| Nau'in EB | RDEB |
| Hanyar haƙuri | N / A |
| Adadin kuɗi | £66,138 (01/11/2011 – 31/10/2013) |
Bayanan aikin
Mutanen da ke fama da recessive dystrophic epidermolysis bullosa (RDEB) sukan sami nau'in ciwon daji na fata da ake kira squamous cell carcinoma (SCC), saboda dalilan da ba mu fahimta sosai ba. Wannan ciwon daji yana da haɗari ga rayuwa don haka yana haifar da babbar matsala ga marasa lafiya na RDEB. Muhimmin direba, wanda ke haifar da sel su ninka, a cikin nau'ikan kansar da yawa shine kwayar halitta da ake kira Pmai-LIke K1 (PLK1). Yana aiki kamar na'urar totur don sa kumburi yayi girma da sauri. Wannan rukunin bincike, yana aiki tare da kudade na DEBRA na baya, sun nuna cewa PLK1 hakika yana aiki a matsayin direba a cikin SCC a cikin marasa lafiya na RDEB da kuma hana aikin PLK1 yana kashe SCC keratinocytes (nau'in kwayar halitta da aka fi sani a cikin fata na fata). Ana iya ɗaukar wannan hanawa azaman ɗaukar ƙafa daga na'ura mai sauri da danna birki a cikin mota! Mahimmanci, yana yin hakan ba tare da shafar ƙwayoyin fata na yau da kullun ba. Yawancin mahadi suna iya hana PLK1 a cikin dakin gwaje-gwaje a ƙarƙashin yanayin gwaji. Kalubale na gaba shine samun ɗaya ko fiye waɗanda suke da tasiri, duk da haka amintaccen amfani da marasa lafiya kuma suyi aiki ba tare da lahani ba. A matsayin wani ɓangare na wannan ƙalubalen wannan aikin ya yi niyya don duba rukunin masu hanawa na PLK1 guda takwas don nemo ɗayan (s) waɗanda zasu iya tasiri a cikin ƙwayoyin SCC daga marasa lafiya na RDEB. Anyi wannan da farko a cikin bututun gwaji sannan a cikin samfurin dakin gwaje-gwaje.
Binciken ya gano wasu mahadi guda uku masu amfani waɗanda ke kashe ƙwayoyin cutar kansa daga wannan yanki na bincike. Ɗayan bai dace da PLK1 ba, amma ƙungiyar bincike na fatan ci gaba da haɓaka don wasu mahadi guda biyu don kawo su zuwa amfani da asibiti don maganin RDEB SCC a cikin shekaru masu zuwa.
Dr Andrew South
Dr Andrew South Mataimakin Farfesa ne a Jami'ar Thomas Jefferson, Philadelphia. Babban abin da ya fi so shi ne fahimtar abubuwan da ke haifar da ci gaba da ci gaba da ciwon daji na squamous cell carcinoma, musamman ma ciwon daji da ke tasowa a cikin marasa lafiya da ke zaune tare da Recessive Dystrophic epidermolysis bullosa. Dr South ya yi aiki a cibiyoyin da ke da tarihin bincike mai zurfi na epidermolysis bullosa, a London, Scotland da kuma Philadelphia a yanzu, kuma ya himmatu don nemo magunguna ga wannan rukunin cututtuka masu lalacewa ta hanyar amfani da tushen binciken kimiyya.